Navigation Links
Northfield Labs Receives FDA Comments

Northfield Laboratories, founded in 1985, is a leading developer of an oxygen-carrying blood substitute. Its product, PolyHeme, is the only blood substitute undergoing clinical trials that has been tested at large enough dosages to be considered a substitute for acute blood loss in trauma and surgical settings. As a result of the process used to manufacture the blood substitute, essentially a solution of polymerized hemoglobin, PolyHeme has a longer shelf life than blood, requires no cross matching and does not transmit disease. //

Northfield Laboratories Inc. reported that it received comments from the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) on its Biologics License Application (BLA), submitted August 2001. CBER indicated that they are seeking additional information before accepting the application for filing and issued a Refusal-to-File letter to the company.

" Refusals for first-time submissions are common,'' said Richard DeWoskin, chief executive officer of Northfield Laboratories Inc. " We are encouraged by the constructive information provided in CBER's initial response, and believe that while the next few months will be busy, there is good reason to expect that modifications resulting from this feedback will help us to progress to the next stage of the application process. The regulatory review will be a multi-stage process. There now will be a period of several weeks during which we will interact with CBER to clarify and come to fully understand the issues in question." said Richard.

The company said the letter included both questions and comments about Northfield's blood substitute, PolyHeme, from CBER. Management said it will quickly begin the process of addressing these issues.
'"/>




Page: 1

Related medicine news :

1. Fifth US Patient Receives Artificial Heart
2. British MPs Say Prostate Cancer Receives Low Priority in the NHS
3. Abbott Receives CE Mark Certification
4. Zactima Receives Fast Track Designation By The FDA
5. East London Receives World Class New Private Hospital Facility
6. Brinda Karat Receives Legal Notice over Ramdev Issue
7. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
8. Medtronic’s Insulin Pump Receives Regulatory Approva
9. Aurobindo Receives Approval from USFDA for anti-AIDS drug
10. Sunscreen Blocking UVA Radiation Receives Federal Approval
11. Eddie Thompson Receives Advanced Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/24/2017)... ... July 24, 2017 , ... Right now, behind ... The agency is hammering out a game plan to implement changes and compromises ... to affect FDA-regulated firms. The new law:, ,     Seeks ways ...
(Date:7/24/2017)... ... 2017 , ... “A Short Walk to the Mailbox”: a remarkable memoir of ... published author, Ed Clark. Ed Clark is a church music director and choral ... minister of music and worship leader for over fifty years. He has a ...
(Date:7/23/2017)... , ... July 23, 2017 , ... A 20-year-long ... St. Louis, and led by the Minneapolis Veterans Administration Health Care System overwhelmingly supports ... the disease offers very few benefits. , In the cases involved with this ...
(Date:7/23/2017)... ... July 23, 2017 , ... “I Am Not Nothin’: The Serpent ... who could barely read and write and a brokenhearted young soldier who turned to ... of age novel about the power of simple faith is the work of published ...
(Date:7/22/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 22, ... ... surgeries take place each year with the majority of patients not requiring pain ... American Orthopaedic Society for Sports Medicine’s Annual Meeting today in Toronto, Ontario, ...
Breaking Medicine News(10 mins):
(Date:6/30/2017)... , June 30, 2017  AVACEN Medical (AVACEN) announced the publication ... research describes the use of its AVACEN Treatment Method ... from fibromyalgia. ... AVACEN Medical ... by chronic widespread pain. It affects approximately 200 to 400 million people ...
(Date:6/27/2017)...  Therapix Biosciences Ltd. (Nasdaq: TRPX ) ... development of cannabinoid-based drugs, today announced that the Company ... New York, NY on Wednesday, ... offering (IPO) of American Depository Shares (ADSs) listed on ... Dr. Elran Haber, Ph.D., Chief Executive Officer of Therapix, ...
(Date:6/20/2017)... and LAGUNA HILLS, Calif. , ... of new data that validate the use of MMprofiler ... patients with multiple myeloma (MM). In a poster presentation ... Hematology Association (EHA) in Madrid, Spain ... MMprofiler for identifying high-risk elderly patients. ...
Breaking Medicine Technology: